story of the week
Camrelizumab vs Placebo in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Camrelizumab Versus Placebo in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN-1st): A Multicentre, Randomised, Double-Blind, Phase 3 Trial
Lancet Oncol 2021 Jun 23;[EPub Ahead of Print], Y Yang, S Qu, J Li, C Hu, M Xu, W Li, T Zhou, L Shen, H Wu, J Lang, G Hu, Z Luo, Z Fu, S Qu, W Feng, X Chen, S Lin, W Zhang, X Li, Y Sun, Z Lin, Q Lin, F Lei, J Long, J Hong, X Huang, L Zeng, P Wang, X He, B Zhang, Q Yang, X Zhang, J Zou, W Fang, L ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.